Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
bluebird bio, Inc. stock logo
BLUE
bluebird bio
$3.73
-3.4%
$6.67
$3.56
$30.90
$36.26M0.76353,629 shs186,319 shs
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$524.24
-2.1%
$614.56
$383.41
$672.19
$163.58B1.372.79 million shs2.52 million shs
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$31.47
-7.3%
$38.23
$11.20
$72.98
$6.99B1.3722.77 million shs19.09 million shs
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$143.83
-0.5%
$144.93
$135.95
$159.64
$37.49B0.698.97 million shs7.98 million shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
bluebird bio, Inc. stock logo
BLUE
bluebird bio
-2.53%-3.50%-38.63%-49.21%-85.65%
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
+0.76%-9.84%-17.63%-9.48%+37.98%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-1.95%-16.98%-23.94%+12.96%+132.72%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
-1.00%-3.39%-1.16%+2.55%-1.65%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
bluebird bio, Inc. stock logo
BLUE
bluebird bio
2.6516 of 5 stars
3.13.00.00.01.72.51.3
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
4.9572 of 5 stars
3.33.04.23.02.13.33.8
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
3.3146 of 5 stars
3.12.00.00.03.03.31.9
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
bluebird bio, Inc. stock logo
BLUE
bluebird bio
2.22
Hold$48.101,189.54% Upside
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.53
Moderate Buy$584.0011.40% Upside
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.27
Hold$37.2318.32% Upside
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
2.76
Moderate Buy$144.090.18% Upside

Current Analyst Ratings Breakdown

Latest XLV, GS, HIMS, and BLUE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/13/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$782.00 ➝ $659.00
3/6/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderperform ➝ Underperform$21.00 ➝ $21.00
3/6/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell ➝ Sell$27.00 ➝ $27.00
2/28/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
2/27/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$690.00 ➝ $660.00
2/26/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$24.00 ➝ $39.00
2/25/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$24.00 ➝ $40.00
2/25/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$24.00 ➝ $35.00
2/25/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSell ➝ Sell$25.00 ➝ $27.00
2/25/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$31.00 ➝ $61.00
2/24/2025
bluebird bio, Inc. stock logo
BLUE
bluebird bio
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$40.00 ➝ $5.00
(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
bluebird bio, Inc. stock logo
BLUE
bluebird bio
$53.12M0.68N/AN/A$35.59 per share0.10
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$53.51B3.06$33.48 per share15.66$324.13 per share1.62
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$1.48B4.73N/AN/A$1.61 per share19.54
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
bluebird bio, Inc. stock logo
BLUE
bluebird bio
-$211.91M-$37.40N/AN/AN/A-565.74%-322.46%-53.17%3/24/2025 (Estimated)
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$14.28B$40.5512.9310.070.8911.32%13.30%0.84%4/21/2025 (Estimated)
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-$23.55M$0.5471.5160.51N/A8.19%10.97%8.29%5/5/2025 (Estimated)
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/A32.25N/AN/AN/AN/AN/A

Latest XLV, GS, HIMS, and BLUE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/24/2025N/A
bluebird bio, Inc. stock logo
BLUE
bluebird bio
-$6.2950N/AN/AN/A$27.07 millionN/A
2/24/2025Q4 2024
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.09$0.11+$0.02$0.11$494.56 million$481.14 million
1/15/2025Q4 2024
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$8.21$11.95+$3.74$11.95$12.36 billion$13.87 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
bluebird bio, Inc. stock logo
BLUE
bluebird bio
N/AN/AN/AN/AN/A
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
$12.002.29%+20.95%29.59%13 Years
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$1.991.38%N/AN/AN/A

Latest XLV, GS, HIMS, and BLUE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/15/2025
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
quarterly$3.002%2/28/20252/28/20253/28/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
bluebird bio, Inc. stock logo
BLUE
bluebird bio
0.37
0.51
0.33
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
2.32
0.67
0.67
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/A
2.14
1.82
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
bluebird bio, Inc. stock logo
BLUE
bluebird bio
5209.72 million9.59 millionOptionable
The Goldman Sachs Group, Inc. stock logo
GS
The Goldman Sachs Group
45,300312.04 million310.35 millionOptionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
1,046222.17 million179.79 millionOptionable
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A260.67 millionN/ANot Optionable

Recent News About These Companies

Health Care Sector Trying to Bounce Back
Time for Defensive Sector ETFs?
Health Care Has Been a Top Sector
Final Trade: FWONK, XLV, MSFT, PEP
Can Health Care ETFs Aid Your Portfolio?
Are healthcare stocks on the rebound?
XLV: Buy Diversity And Growth

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
bluebird bio stock logo

bluebird bio NASDAQ:BLUE

$3.73 -0.13 (-3.37%)
Closing price 04:00 PM Eastern
Extended Trading
$3.72 -0.01 (-0.27%)
As of 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

The Goldman Sachs Group stock logo

The Goldman Sachs Group NYSE:GS

$524.24 -11.47 (-2.14%)
Closing price 03:59 PM Eastern
Extended Trading
$527.88 +3.64 (+0.69%)
As of 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Goldman Sachs Group, Inc., a financial institution, provides a range of financial services for corporations, financial institutions, governments, and individuals worldwide. It operates through Global Banking & Markets, Asset & Wealth Management, and Platform Solutions segments. The Global Banking & Markets segment provides financial advisory services, including strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, and spin-offs; and relationship lending, and acquisition financing, as well as secured lending, through structured credit and asset-backed lending and involved in financing under securities to resale agreements. This segment also offers client execution activities for cash and derivative instruments; credit and interest rate products; and provision of mortgages, currencies, commodities, and equities related products, as well as underwriting services. The Asset & Wealth Management segment manages assets across various classes, including equity, fixed income, hedge funds, credit funds, private equity, real estate, currencies, and commodities; and provides customized investment advisory solutions, wealth advisory services, personalized financial planning, and private banking services, as well as invests in corporate equity, credit, real estate, and infrastructure assets. The Platform Solutions segment offers credit cards and point-of-sale financing for purchase of goods or services. This segment also provides cash management services, such as deposit-taking and payment solutions for corporate and institutional clients. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.

Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$31.46 -2.47 (-7.26%)
Closing price 03:59 PM Eastern
Extended Trading
$31.44 -0.03 (-0.08%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Health Care Select Sector SPDR Fund stock logo

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$143.83 -0.77 (-0.53%)
Closing price 04:10 PM Eastern
Extended Trading
$143.98 +0.14 (+0.10%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.